|
Clinical efficacy of different blood purification modalities for the treatment of patients with hypertriglyceridemia pancreatitis
2018, 17 (03):
145-150.
doi: 10.3969/j.issn.1671-4091.2018.03.001
【Abstract】Objective To evaluate different blood purification modalities on the clinical efficacy and prognosis in patients with hypertriglyceridemia pancreatitis (HTGP). Methods Clinical data of the 63 patients with moderate-to-severe HTGP treated with blood purification in our hospital in the period from March 2012 to March 2017 were recruited. The patients were divided into two groups based on blood purification modalities: combined group treated with continuous veno-venous hemofiltration (CVVH) plus hemoperfusion(HP) (n=33), and CVVH group treated with CVVH only (n=30). Vital signs, serum levels of triglyceride (TG), amylase (AMS), interleukin-6 (IL-6) and blood calcium (Ca2+ ), white blood cells (WBC), hemoglobin (Hb), platelets (PLT), and scores of acute physiology and chronic health evaluation (APACHE II) were compared between the two groups before treatment and after the treatment for 24 hours, 72 hours and one week. Duration from abnormal to target TG level, number of blood purification times, recovery period to stable disease status, hospitalization day and mortality rate were also compared between the two groups. Results There were no significant differences in vital signs, serum TG level, other laboratory tests including inflammatory makers and internal environment indices, and APACHE II scores between the two groups before the treatment
(P>0.05). After the treatment, clinical indices were significantly improved in combined group and CVVH group, including temperature, respiratory rate, heart rate, TG, AMS, Ca2+ , IL-6, WBC and APACHE II score, but HB and PLT were not changed (for temperature, F=87.116, P=0.021 and F=46.658, P=0.038, respectively; for respiratory rate, F=276.236, P<0.001 and F=109.768, P=0.004, respectively; for heart rate, F=207.657, P<0.001 and F=96.857, P=0.023, respectively; for TG, F=16.853, P<0.001 and F=4.315, P=0.015, respectively; for AMS, F=10.254, P<0.001 and F=8.795, P<0.001, respectively; for Ca2+, F=23.795, P<0.001 and F=22.836, P<0.001, respectively; for IL-6, F=13.982, P<0.001 and F=10.352, P=0.005, respectively; for WBC, F=17.249, P<0.001 and F=7.582, P=0.017, respectively; for APACHE II score, F=277.158, P<0.001 and F=63.052, P<0.001, respectively). Serum TG, AMS and APACHE II score decreased faster in combined group than in CVVH group (7.14±1.04 vs. 10.83±1.10 mmol/L, t=3.334, P=0.015 for TG; 457.80±60.56 vs. 705.56±72.46U/L, t=3.604, P=0.010 for AMS; 8.96±0.77 vs. 10.63±0.93, t=3.726, P=0.001 for APACHEⅡ score), and the differences in decrease rates between the two groups became more remarkable after the treatment for 24 hours. The durations to reach safe serum levels, normal vital signs and WBC were shorter in combined group than in CVVH group (t=4.090, P=0.001 for TG; t=1.843, P=0.032 for AMS; t= 8.059, P<0.001 for APACHE II score; t=15.356, P=0.035 for temperature; t=9.909, P=0.035 for respiratory rate; t=9.729, P<0.001 for heart rate; t=2.861, P=0.007 for WBC). Mortality rate was also lower in combined group than in CVVH group but without statistical significance, probably due to insufficient case number (0% vs. 10.00%, corrected χ2=1.611, P=0.204). The duration to achieve normal TG and stable disease status, blood purification times, hospitalization day were less in combined group than in CVVH group (2.58±1.45 vs.7.71±2.69 days, t=4.866, P=0.002 for TG; 7.46±3.05 vs.16.14±4.10 days, t=6.136, P<0.001 for stable disease status; 2.38±0.98 vs. 7.57±2.57 times, t=5.232, P=0.002 for blood purification times; 20.00±12.12 vs. 30.00± 6.40 days, t=2.088, P=0.045 for hospitalization days). Consequently, prognosis was better in combined group than in CVVH group. Conclusion CVVH combined with hemoperfusion has the advantages of quickly lowering serum TG and blocking inflammation responses, resulting in a better therapeutic effects and improved disease condition in a short period of time.
Metrics
|